Little is known about HB-EGF–EGFR signaling in hematological cancers, such as multiple myeloma (MM), a lethal malignancy of bone marrow plasma cells that is often anticipated by a preneoplastic phase termed monoclonal gammopathy of undetermined significance (MGUS) [13]. This evidence concerns the gene EGFR and Miyoshi myopathy.